Welcome to our dedicated page for Pulse Biosciences SEC filings (Ticker: PLSE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage disclosures can feel like a lab manual鈥攅specially when Pulse Biosciences鈥� Nano-Pulse Stimulation milestones, FDA submissions, and funding rounds are scattered across hundreds of SEC pages. Finding R&D costs or tracking when executives buy shares shouldn鈥檛 require a PhD.
Stock Titan鈥檚 AI reads every Pulse Biosciences annual report 10-K simplified, Pulse Biosciences quarterly earnings report 10-Q filing, and Pulse Biosciences 8-K material events explained the moment they hit EDGAR. Our platform converts technical jargon into clear summaries, flags cash-runway updates, and links clinical-trial progress to revenue outlook鈥攕o you can act before the market digests the details.
Need fast answers? Ask natural questions like 鈥渦nderstanding Pulse Biosciences SEC documents with AI鈥� or 鈥淧ulse Biosciences proxy statement executive compensation鈥� and jump straight to the line items that matter. AG真人官方-time alerts surface every Pulse Biosciences insider trading Form 4 transactions, while heat-maps highlight patterns in Pulse Biosciences executive stock transactions Form 4. Our coverage spans:
- 10-K & 10-Q: cash burn, clinical spend, segment results with AI commentary
- 8-K: trial results, device clearances, leadership changes
- DEF 14A: board bios and pay packages
- Form 4: insider buys and sells鈥�Pulse Biosciences Form 4 insider transactions real-time
Whether you鈥檙e evaluating NPS commercialization odds or scanning a Pulse Biosciences earnings report filing analysis, our AI-powered summaries, expert annotations, and instant notifications ensure Pulse Biosciences SEC filings are explained simply鈥攕o you save hours and never miss a signal.
Pulse Biosciences (PLSE) reported no revenue and continues to operate at a loss while advancing its Nano-pulse Stimulation (NPS) product pipeline. Cash and cash equivalents were $106.3 million at June 30, 2025, with total assets of $120.3 million and stockholders' equity of $104.5 million. The company recorded a net loss of $19.2 million for the three months ended June 30, 2025 and $36.0 million for the six months ended June 30, 2025. Operating cash used totaled $26.3 million for the six-month period and stock-based compensation expense was $10.9 million for the same period. The company has an accumulated deficit of $426.5 million and reports no material cash flows from operations.
The company completed a $60.0 million rights offering in July 2024 (majority purchased by Robert Duggan) and has received $63.5 million in cumulative gross proceeds from exercises of related warrants including $14.1 million during the six months ended June 30, 2025. Regulatory and clinical milestones include FDA 510(k) clearances for the nsPFA Percutaneous Electrode System (initial and a second needle size), placement of CellFX at nine U.S. sites with over 140 patient treatments to date, Breakthrough Device designation and TAP enrollment for the cardiac surgical clamp, and active IDE interactions and planned pivotal U.S. trials for cardiac devices.
Pulse Biosciences, Inc. (Nasdaq: PLSE) filed a Form 8-K announcing the appointment of Steven T. Weber as Vice President of Accounting & Global Corporate Controller, effective 14 Jul 2025. Weber will also assume the role of principal accounting officer, succeeding the prior incumbent (not specified in the filing). The 25-year finance veteran most recently served as SVP, Corporate Controller & PAO at IGM Biosciences and previously held senior roles at Aeglea Biotherapeutics and PwC.
Compensation & equity incentives: Weber鈥檚 cash compensation (base salary and target bonus) aligns with existing VP pay bands; specific dollar amounts were not disclosed. He received a non-statutory option for 55,000 shares at an exercise price of $16.03 (close of 11 Jul 2025). Vesting structure:
- Time-based: 27,500 shares vest 25% on the 1-year anniversary then quarterly over three additional years.
- Performance-based: up to 27,500 shares vest in four equal tranches tied to market-cap milestones of $1.5 B, $2.25 B, $3.0 B, and $4.0 B, each requiring 270 consecutive days and no earlier than year-end 2026-2029.
Weber signed standard inventions, confidentiality, non-competition and indemnification agreements. There are no related-party transactions or family relationships disclosed.
Investor takeaways: This is a governance-focused event that strengthens the finance function with a seasoned CPA. The equity package is modest (~0.2% of shares outstanding) and heavily performance-weighted, aligning Weber鈥檚 incentives with long-term shareholder value. No immediate financial impact or guidance changes were provided.
FAQ
What is the current stock price of Pulse Biosciences (PLSE)?
What is the market cap of Pulse Biosciences (PLSE)?
